COVAX

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

The mRNA-based therapy, used with Keytruda, is designed specifically for each patient

Mukherjee has previously held senior leadership roles at Moderna and GSK

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

More than 600,000 people in the US were hospitalised due to flu-related illness last year

The vaccine is already approved in the US for use in adults aged 60 years and older

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

The Committee has advised offering the vaccine to those at high risk of serious disease